Loading...
Late Stage Ocular Therapy Risks Will Eventually Reward Sustained Release Retinal Franchise Potential
AN
AnalystLowTarget
Not Invested
Community Contributor
Published
07 Jan 26
Views
10
07 Jan
US$13.58
AnalystLowTarget's Fair Value
US$20.00
32.1% undervalued intrinsic discount1Y
87.6%7D
5.0%1Y
87.6%7D
5.0%You can edit this narrative until Jan 8 8:05 AM. Then, changes will post as Updates.
Author's Valuation
US$2032.1% undervalued intrinsic discount
AnalystLowTarget Fair Value